MELISA Institute is a renowned biotechnology research institution dedicated to developing health solutions for various areas of human life sciences, with a particular emphasis on maternal and fetal health, human reproduction, and women's health. Their integrated approach includes basic sciences, epidemiology, and clinical medicine, allowing them to conduct advanced research in proteogenomics and produce medical products with diagnostic or therapeutic applications. One of MELISA's leading investigational therapies is Previfenon®️, which is being developed as a potential prenatal therapeutic agent for trisomy 21 during the third trimester of pregnancy.

This therapy aims to inhibit the overdose of DYRK1A and improve neurodevelopment after birth. Furthermore, Previfenon is also being investigated as a broad spectrum chemoprophylaxis method to prevent and control the impact of epidemics caused by emergent viruses such as SARS-CoV-2, thanks to the immunomodulatory and antiviral effects of its components EGCG and zinc. Located in San Pedro de la Paz, Bio Bio, Chile, MELISA Institute is committed to exploring the social, economic, and biological determinants of health on a population level.

For inquiries about their services, please contact them through the provided email or phone number